Drug Shortage Report for INTEGRILIN
| Report ID | 9382 |
| Drug Identification Number | 02240352 |
| Brand name | INTEGRILIN |
| Common or Proper name | Eptifibatide Injection |
| Company Name | MERCK CANADA INC |
| Market Status | CANCELLED POST MARKET |
| Active Ingredient(s) | EPTIFIBATIDE |
| Strength(s) | 2MG |
| Dosage form(s) | SOLUTION |
| Route of administration | INTRAVENOUS |
| Packaging size | 20MG/10ML vial |
| ATC code | B01AC |
| ATC description | ANTITHROMBOTIC AGENTS |
| Reason for shortage | Delay in shipping of the drug. |
| Anticipated start date | |
| Actual start date | 2017-07-05 |
| Estimated end date | 2017-08-11 |
| Actual end date | 2017-08-09 |
| Shortage status | Resolved |
| Updated date | 2017-08-10 |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 16750 ROUTE TRANSCANADIENNE KIRKLAND, QUEBEC CANADA H9H 4M7 |
| Company contact information | 1-800-567-2594 medinfocanada@merck.com |
Version History
Click on "Compare" below to view the full report history and compare to other versions.